

# US Bioservices Dispensing Gilead's EPCLUSA<sup>®</sup> for All Genotypes of HCV

The U.S. Food and Drug Administration recently approved Gilead's EPCLUSA<sup>®</sup> (sofosbuvir 400 mg/velpatasvir 100 mg), the first oral single tablet regimen for the treatment of adults with genotypes 1-6 chronic hepatitis C virus (HCV) infection. EPCLUSA is a fixed-dose tablet that combines sofosbuvir, a drug approved in 2013, and the new drug velpatasvir.

EPCLUSA is significant for patients with genotypes 2 and 3, as this is the first single tablet regimen approved for this population who previously had more complex and costly treatments.

US Bioservices has been selected as an authorized specialty pharmacy for this new pan-genotype HCV therapy and will dispense EPCLUSA as soon as it is available for distribution.

## More Information

- US Bioservices  
(866) 223-7914 or fax (888) 418-7246  
[usbioservices.com](http://usbioservices.com)
- Gilead Website  
[Product Insert for Epclusa](#)
- FDA Press Release  
<http://www.fda.gov/newsevents/newsroom/pressannouncements/ucm508915.htm>